CBS highlights NIH’s launch of ACTIV-2 and ACTIV-3 to develop monoclonal antibody treatment for COVID-19 | National Institutes of Health (NIH)

CBS highlights NIH’s launch of ACTIV-2 and ACTIV-3 to develop monoclonal antibody treatment for COVID-19 | National Institutes of Health (NIH)

CBS highlights NIH’s launch of ACTIV-2 and ACTIV-3 to develop monoclonal antibody treatment for COVID-19

Dr. Collins talks to CBS’ Jonathan LaPook about the launch of ACTIV-2 and ACTIV-3 inpatient and outpatient clinical trials to test effectiveness of monoclonal antibody treatment for COVID-19.

https://www.cbsnews.com/news/covid-treatment-monoclonal-antibodies-vaccine-eli-l…